Pfizer hits setback in obesity drug race as GLP-1 trial halts
Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver injury. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination Overtime to break down the details, as well as preview what to watch as Johnson & Johnson (JNJ) prepares to report earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.